Literature DB >> 23943669

Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results.

.   

Abstract

Entities:  

Year:  2013        PMID： 23943669      PMCID： PMC3740810     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  3 in total

1.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.

Authors:  William J Sandborn; Gert van Assche; Walter Reinisch; Jean-Frederic Colombel; Geert D'Haens; Douglas C Wolf; Martina Kron; Mary Beth Tighe; Andreas Lazar; Roopal B Thakkar
Journal:  Gastroenterology       Date:  2011-11-04       Impact factor: 22.682

2.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.

Authors:  Walter Reinisch; William J Sandborn; Daniel W Hommes; Geert D'Haens; Stephen Hanauer; Stefan Schreiber; Remo Panaccione; Richard N Fedorak; Mary Beth Tighe; Bidan Huang; Wendy Kampman; Andreas Lazar; Roopal Thakkar
Journal:  Gut       Date:  2011-01-05       Impact factor: 23.059

3.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245
  3 in total
  3 in total

1.  Long-Term Outcomes of Immunosuppression-Naïve Steroid Responders Following Hospitalization for Ulcerative Colitis.

Authors:  Amar Vedamurthy; Louise Xu; Jay Luther; Francis Colizzo; John J Garber; Hamed Khalili; Ashwin N Ananthakrishnan
Journal:  Dig Dis Sci       Date:  2018-06-27       Impact factor: 3.199

2.  Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial.

Authors:  Makoto Naganuma; Yoko Yokoyama; Satoshi Motoya; Kenji Watanabe; Koji Sawada; Fumito Hirai; Takayuki Yamamoto; Hiroyuki Hanai; Teppei Omori; Takanori Kanai; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2019-12-06       Impact factor: 7.527

Review 3.  An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis.

Authors:  Francesca Ferretti; Rosanna Cannatelli; Maria Camilla Monico; Giovanni Maconi; Sandro Ardizzone
Journal:  J Clin Med       Date:  2022-04-20       Impact factor: 4.964
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.